People who join this study must have already received at least one dose of RP1, RP2, or RP3 in a previous study and have either finished that study or stopped participating in it. During this study, doctors will watch for specific types of delayed health problems that might be related to the treatment. These include new cancers, new or worsening problems with the nervous system (which controls things like movement and sensation), new or worsening problems with the immune system (which protects the body from disease) or conditions where the immune system attacks the body itself, new blood disorders, new infections related to the treatment, and new infections caused by the herpes virus.

The study will follow patients for several years to collect information about their health and any new medical problems that develop. This helps researchers understand if there are any long-term effects from treatment with these experimental medicines. Patients will be asked to report any new health issues to their doctors, who will record this information as part of the study.

The purpose of this study is to determine how well patients respond to local treatments (such as radiotherapy, surgery, or electrochemotherapy) when they are already receiving encorafenib and binimetinib. These local treatments will be used on specific tumor sites while patients continue taking their regular medication.

During the study, patients will receive encorafenib and binimetinib as oral medications daily. When certain tumors remain stable or continue to grow while other tumors are responding to treatment, doctors may use local treatments like radiotherapy, surgery, or electrochemotherapy to target these specific areas. Patients will be monitored regularly to check how their cancer responds to this combination of treatments and to watch for any side effects.

The purpose of this study is to evaluate how well these two medications work together in treating patients with advanced melanoma who have already received other treatments. Participants in the study will receive these medications through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for up to 24 months, during which time participants will be monitored for their response to the treatment and any side effects they may experience.

Throughout the study, researchers will assess various outcomes, such as how many patients experience a reduction in their cancer, how long patients live without their cancer getting worse, and the overall survival time. The study will also look at the safety of the treatment combination by tracking any adverse events, which are unwanted effects that may occur during the study. The goal is to gather information that could lead to better treatment options for people with advanced melanoma.

The purpose of the study is to find the best doses of these medications when used together and to see how well they work in treating melanoma. The study will also look at how safe the treatment is and how well patients can tolerate it. Participants will receive the treatment and be monitored for any side effects or changes in their health. The study will be conducted in two phases: Phase 1b will focus on determining the recommended doses, and Phase 2a will assess the treatment’s effectiveness in shrinking the cancer.

Throughout the study, participants will have regular check-ups to monitor their health and the progress of the treatment. This includes tracking any side effects and measuring how the cancer responds to the treatment. The study aims to provide valuable information on the potential benefits and risks of using BI-1607 in combination with Ipilimumab and Pembrolizumab for treating unresectable or metastatic melanoma.

The research aims to determine if this combination of treatments is safe and how well patients can tolerate it. During the study, participants will receive TIL cells and nivolumab first, followed by the addition of Peginterferon alfa-2a. The study also uses Zirconium Zr 89 crefmirlimab berdoxam, a special imaging substance that helps doctors see how the treatment is working in the body.

Throughout the study, doctors will monitor participants’ health closely through regular check-ups, blood tests, and imaging scans. They will track how the cancer responds to treatment and watch for any side effects. The study will continue for several years to gather comprehensive information about how well this treatment combination works for metastatic melanoma patients.

The purpose of the study is to evaluate how effective and safe ABP 206 is compared to OPDIVO® in patients who have not received any previous treatment for their advanced melanoma. Participants in the study will receive either ABP 206 or OPDIVO® for a period of up to 24 months. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatments. The study will monitor the response to the treatment, including any changes in the size of the melanoma, and will also track any side effects or immune reactions that may occur.

Throughout the study, participants will have regular check-ups to assess their health and the progress of their melanoma. The study aims to provide valuable information on the effectiveness of ABP 206 compared to OPDIVO® in treating unresectable or metastatic melanoma, potentially offering new insights into treatment options for this condition.

The purpose of the study is to assess the long-term safety of these medications. Participants will continue to receive their current treatment, either as a single medication or in combination, depending on what they were receiving in the previous study. The study will monitor the occurrence of any side effects or adverse events to ensure the ongoing safety of the treatment. Patients will have regular check-ups with their healthcare providers to evaluate their health and the effectiveness of the treatment.

This study is designed for patients who have already been receiving dabrafenib and/or trametinib and have shown compliance with the treatment plan. The study will continue until the end of 2027, allowing patients to maintain their treatment regimen under the supervision of their healthcare team. The goal is to ensure that patients who are benefiting from these medications can continue to do so safely over a longer period.

The purpose of the study is to see if using Dacarbazine first can make the cancer more responsive to the immunotherapy drugs. Participants will receive Dacarbazine initially, and then, after a certain period, they will be given the immunotherapy drugs. The study aims to improve the overall response rate, which means seeing how well the cancer responds to the treatment, and to increase the overall survival of the participants. The study will also collect biological samples like tissue, blood, and stool to understand the changes in the immune system during the treatment.

Participants will be monitored throughout the study to assess their quality of life and any changes in their condition. The study is designed to last for a specific period, and the results will help determine if this treatment approach is effective for people with Melanoma that has not responded to previous treatments. The study does not involve explaining the meaning of a placebo, as it is not part of this trial.

The purpose of this research is to evaluate how well two different doses of RO7247669 work in people who have not received any previous treatment for their melanoma. The medicine will be given through intravenous infusion, which means it is delivered directly into a vein. Participants will receive either 600 mg or 1200 mg of the medication every three weeks.

During the study, participants will receive regular medical check-ups and scans to monitor their condition. The treatment period may last up to 24 months. The medicine being tested is designed to help the body’s immune system fight against cancer cells by targeting two specific proteins called PD-1 and LAG3. This is different from traditional chemotherapy as it works by enhancing the body’s natural defense mechanisms.

Participants in the study will receive either the combination of binimetinib, encorafenib, and pembrolizumab alone or the same combination with the addition of SRS. The study will monitor how the cancer responds to these treatments and how long it takes for the cancer to progress in the brain. The trial will also look at the overall health and quality of life of the participants during the study period. The study is expected to continue until 2030, with participants being closely monitored throughout the trial.

The purpose of the study is to evaluate how well diclofenac works when added to the existing PD-1 inhibitor therapy in patients whose cancer has not progressed beyond a stable state. Diclofenac is a medication commonly used to reduce inflammation and pain. In this study, it is being tested to see if it can enhance the effects of the PD-1 inhibitors. The study will involve regular monitoring of the patients’ health and response to the treatment over a period of time.

Participants in the study will receive diclofenac in addition to their ongoing PD-1 inhibitor therapy. The treatment will be administered according to a set schedule, and patients will be closely observed to assess any changes in their condition. The study aims to determine if the combination of these treatments can lead to better outcomes for patients with metastatic melanoma.

Participants in the study will receive the treatment combination over a period of time, with INCB099280 being taken orally and Ipilimumab administered through an intravenous infusion. The study will monitor the participants for any side effects or reactions to the treatment. The goal is to find the right dose that is both safe and effective for patients. The study will also compare the effects of the treatment combination to a placebo to better understand its impact.

Throughout the study, participants will have regular check-ups and tests to assess their health and the progress of their treatment. These tests will help researchers understand how the treatment affects the body and whether it helps control the growth of the tumors. The study is expected to continue for several years, allowing researchers to gather comprehensive data on the treatment’s safety and effectiveness.

The purpose of the study is to compare how well patients do when treated with the combination of relatlimab and nivolumab versus nivolumab alone. Participants in the study will receive either the combination treatment or nivolumab by itself. The study is designed to be “double-blind,” meaning neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments being studied.

Throughout the study, participants will receive their assigned treatment through an infusion, which is a way of delivering medication directly into the bloodstream. The study will monitor how long participants live without their cancer getting worse, known as progression-free survival. Other aspects, such as overall survival and the response of the cancer to the treatment, will also be observed. The study aims to provide valuable information on whether the combination of relatlimab and nivolumab offers better outcomes for patients with advanced melanoma compared to nivolumab alone.

The purpose of the study is to compare the combination of IO102-IO103 and pembrolizumab against pembrolizumab alone. Participants in the study will receive either the combination treatment or pembrolizumab by itself. The study will monitor how long patients live without the cancer getting worse, which is known as progression-free survival. The trial will also look at other outcomes, such as the overall response rate, which measures how many patients experience a reduction in cancer size, and overall survival, which tracks how long patients live after starting the treatment.

Participants will be randomly assigned to one of the two treatment groups and will receive their treatment through injections. The study will continue for a period of up to 24 months, during which time patients will be regularly monitored to assess the effectiveness and safety of the treatments. This trial aims to provide valuable information on whether the new combination treatment can offer better results for patients with advanced melanoma.

The purpose of this study is to evaluate the safety and how well the treatment works when using ATL001 alone and in combination with nivolumab. Participants in the study will receive these treatments through an infusion, which means the medication is given directly into the bloodstream through a vein. The study will monitor participants over a period of time to observe any side effects and to see how the cancer responds to the treatment. The study aims to understand if this combination can help control the cancer and improve outcomes for patients with metastatic or recurrent melanoma.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the effects of the treatment. The study will also look at changes in the size of the tumor and overall survival rates. This research is important for developing new ways to treat melanoma and potentially improve the quality of life for those affected by this disease.

The purpose of this study is to compare the combination of RO7198457 and Pembrolizumab against Pembrolizumab alone in patients who have not received prior treatment for their advanced melanoma. The study will monitor how long patients live without their cancer getting worse, known as progression-free survival. Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for up to 24 months, during which time the safety and effectiveness of the treatments will be closely observed.

Throughout the study, researchers will also look at other important factors, such as the overall survival of patients, the response of the cancer to the treatment, and any changes in the patients’ quality of life. Additionally, the study will track any side effects experienced by participants to ensure the treatments are safe. This trial aims to provide valuable information on whether the combination of RO7198457 and Pembrolizumab offers a better treatment option for patients with advanced melanoma compared to Pembrolizumab alone.

The purpose of the study is to compare the effects of the combination of Encorafenib, Binimetinib, and Pembrolizumab against a placebo combined with Pembrolizumab. Participants will be randomly assigned to receive either the combination of the three medications or the placebo with Pembrolizumab. The study will last for up to 24 months, during which participants will receive regular treatments and check-ups to monitor their health and the progress of the melanoma.

This trial aims to determine if the combination of these medications can improve outcomes for patients with this specific type of melanoma. The study will also assess the safety of the medication combination and monitor any side effects that may occur. Participants will be closely observed by healthcare professionals throughout the study to ensure their well-being and to gather important information about the treatment’s effectiveness.

The purpose of the study is to compare two different treatment combinations to see which is more effective. One group of participants will receive a combination of three medications: encorafenib, binimetinib, and pembrolizumab. The other group will receive a combination of two medications: nivolumab and ipilimumab. These medications are given to help the immune system target and destroy cancer cells. Encorafenib and binimetinib are taken as tablets, while pembrolizumab, nivolumab, and ipilimumab are given through an infusion into a vein.

Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for a period of time, during which participants will receive their assigned treatment and be monitored regularly by the study team. The goal is to see which treatment combination works better in controlling the cancer and improving the participants’ health. The study will also look at the safety of the treatments and any side effects that may occur. Participants will have regular check-ups and tests to track their progress and the effects of the treatment.

The purpose of the study is to evaluate how well these treatment combinations work in shrinking the tumors and to assess their safety. Participants in the study will receive one of the treatment combinations or a placebo. The study will monitor the response of the cancer to the treatment and any side effects that may occur. The study is divided into two parts and will involve regular check-ups and assessments to track the progress of the treatment.

Throughout the study, participants will undergo various tests and evaluations to measure the effectiveness of the treatment. This includes imaging tests to see how the cancer is responding and regular health check-ups to monitor for any side effects. The study aims to provide valuable information on the potential benefits and risks of these treatment combinations for patients with advanced melanoma.

The purpose of the study is to find out if adding EVX-01 to pembrolizumab can help patients with melanoma that cannot be removed by surgery or has spread to other parts of the body. The study will look at how well the combination of these treatments works compared to historical outcomes with pembrolizumab alone. Participants in the study will receive both treatments and will be monitored to see how their cancer responds over time.

During the study, participants will receive pembrolizumab through an infusion, which means the medicine is given directly into a vein. EVX-01 will be given as an injection into a muscle. The study will last for up to 24 months, and participants will have regular check-ups to monitor their health and the progress of their cancer. The study aims to provide more information on the safety and effectiveness of using EVX-01 with pembrolizumab for treating this type of melanoma.

The purpose of the study is to determine how effective PET-DOPA is in identifying newly diagnosed, untreated brain metastases that are at least 5 mm in size, as seen on an MRI scan. Participants in the study will undergo PET-DOPA imaging to see how well it can detect these metastases compared to traditional MRI scans. The study will also explore how PET-DOPA can help in understanding the characteristics of these brain metastases.

Throughout the study, participants will receive the PET-DOPA injection and undergo imaging to assess the presence and characteristics of brain metastases. The study aims to provide valuable information on the sensitivity of PET-DOPA in detecting brain metastases from different types of primary cancers, including specific subtypes of lung cancer, melanoma, and breast cancer. This research could potentially lead to better diagnostic tools for patients with these conditions.

The goal of this study is to continue providing the treatment to patients who have already participated in earlier phases of similar studies but still need ongoing therapy since they cannot access these medicines locally. This means the therapy will continue for patients who are still benefiting from it according to assessments by their doctors.

The study does not provide detailed procedures but involves using these medicines to see if the patients continue to respond positively to the treatment therapies. This ongoing treatment will allow the observation of the treatments’ effects over a longer period and help determine the best use of these drugs in managing cancer. Some patients might be given a placebo, which is a substance with no therapeutic effect used in trials to test the effectiveness of another drug.

The purpose of the study is to assess the safety and potential benefits of these treatments in patients with advanced solid tumors. The study is divided into two parts. In the first part, researchers will focus on understanding how safe and tolerable the combination of ICT01 and low-dose interleukin-2 is, both with and without pembrolizumab. In the second part, the study will look at how well these treatments work in controlling the cancer. Patients will receive the treatments and be monitored for any side effects and changes in their cancer status.

Participants in the study will receive the treatments over a period of time and will have regular check-ups to monitor their health and the progress of their cancer. The study aims to gather information on how the cancer responds to the treatments and any side effects that may occur. This information will help determine if these treatment combinations could be beneficial for patients with these types of advanced cancers in the future.

Participants in the study will take INCB099280 in the form of a film-coated tablet. The study will test different doses of the medication, specifically 400 mg, 600 mg, and 800 mg, taken twice a day. The treatment period can last up to 24 weeks. During the study, participants will be monitored for any side effects and changes in their condition. Some participants may receive a placebo, which is a tablet that looks like the treatment but does not contain the active medication.

The study aims to gather information on how the treatment affects the tumors, including whether it can shrink them or stop them from growing. It will also look at how long any positive effects last and how the treatment impacts the overall health and survival of the participants. The results will help determine if INCB099280 could be a useful treatment option for people with these types of cancer in the future.

The purpose of the study is to assess how safe these treatments are and how well they work in treating melanoma that has spread to the brain. Participants will receive one or more of these treatments, or a placebo, and their health will be monitored closely throughout the study. The study will look at how the cancer responds to the treatments, including any changes in the size of the tumors, and will also track any side effects experienced by participants.

Participants in the study will undergo regular check-ups and imaging tests, such as MRI scans, to evaluate the progress of the treatment. The study aims to provide valuable information on the potential benefits and risks of these treatment combinations for people with advanced melanoma, particularly those whose cancer has spread to the brain.

The purpose of this study is to evaluate how effective botensilimab is when used alone and in combination with balstilimab. Participants in the study will receive these medications as a solution through an infusion, which means the medicine is given directly into the bloodstream. The study will monitor the participants over a period to see how their cancer responds to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

Throughout the study, researchers will observe the participants to determine the objective response rate, which measures how well the cancer shrinks or disappears after treatment. They will also look at progression-free survival, which is the length of time during and after treatment that the cancer does not get worse, and overall survival, which is the time from the start of the study until death from any cause. The study aims to provide valuable information on the potential benefits of these new treatments for patients with advanced melanoma.

Participants in the study will receive either the intravenous or subcutaneous form of the medication. The study will monitor how the body absorbs the medications and will also look at how well the cancer responds to the treatment. This includes checking if the cancer decreases in size or disappears after treatment. The study will take place over a period of time, and participants will be closely observed to ensure their safety and to gather information about the effectiveness of the treatment.

The trial is open to individuals who have not received prior systemic treatment for their melanoma, except for certain previous therapies if any side effects have stabilized. The study aims to provide valuable information on whether the subcutaneous method of administering the medications is as effective as the intravenous method, potentially offering a more convenient option for patients in the future.

Participants in the study will receive nivolumab in different forms, including subcutaneous injections and intravenous infusions. The study will observe how the medication moves through the body and how it is absorbed, distributed, and eliminated. This will help researchers understand the best way to administer nivolumab for treating these cancers. The study will also monitor for any side effects or reactions to the medication, including any allergic reactions or the development of antibodies against nivolumab.

The study is expected to continue until August 2025. During this time, participants will receive regular doses of the medication and will be closely monitored by the research team. The information gathered from this study will contribute to the understanding of nivolumab’s effectiveness and safety in treating various types of cancer.

During the study, participants will receive either the tebentafusp regimen or a treatment selected by their doctor, which may include medications like diphenhydramine, dexamethasone, or paracetamol. Tebentafusp and pembrolizumab are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. The study will last for a period of up to 24 months, during which the participants’ health and response to the treatment will be closely monitored.

The study aims to determine if the tebentafusp regimen can lead to a greater reduction in cancer markers and improve overall survival compared to the other treatments. Participants will be monitored for any side effects and changes in their health throughout the study. The results will help researchers understand the potential benefits of tebentafusp for people with advanced melanoma and guide future treatment options.

Participants in the study will receive the treatments through an injection into a vein, which is known as intravenous use. The study will observe how the cancer responds to the treatment over time. Some participants will receive nemvaleukin alfa by itself, while others will receive it together with pembrolizumab. The study aims to see if these treatments can help reduce the size of the cancer or stop it from growing.

The study will take place over a period of time, during which participants will have regular visits to monitor their health and the effects of the treatment. The study will also look at the safety of the treatments and any side effects that may occur. The goal is to gather information that could help improve treatment options for people with these types of melanoma in the future.

Participants in the study will be randomly assigned to receive either the combination of Tucidinostat and Nivolumab or the placebo and Nivolumab. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. The study will last for a period of up to 24 months, during which participants will receive regular check-ups and monitoring to assess the progress of their condition.

The main goal is to measure how long patients live without their cancer worsening, known as progression-free survival. Other important outcomes include the overall response to the treatment and the overall survival of the participants. This study aims to provide valuable information on the effectiveness of combining Tucidinostat with Nivolumab in treating advanced melanoma.